Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Cerevel Therapeutics Stock Is Shooting Through the Roof Today

By Cory Renauer - Jun 29, 2021 at 12:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Positive topline results from the company's schizophrenia candidate were better than expected.

What happened

Shares of Cerevel Therapeutics Holdings (CERE -1.23%) are surging after the Pfizer (PFE -0.72%) spinoff reported topline results for an experimental new schizophrenia drug.

Successful topline data make it look like Pfizer shouldn't have spun off a handful of neuroscience therapy candidates three years ago. Investors excited about the road ahead of Cerevel pushed the stock 95.8% higher as of 11:47 a.m. EDT on Tuesday.

Excited investor looking at a laptop.

Image source: Getty Images.

So what 

Cerevel Therapeutics doesn't have any products to sell at the moment, but that could change in a couple of years. This morning, expectations for the clinical-stage biotech's lead drug candidate, CVL-231, shot way up thanks to successful data from a phase 1 clinical trial with schizophrenia patients.

During the placebo-controlled trial, which was designed to find a safe dosage for use in upcoming studies, patients treated with a 20 milligram daily dose of CVL-231, and patients treated with a 30 milligram daily dose showed significant improvements.

Average scores on the positive and negative syndrome scale (PANSS) from the 30-milligram cohort were 19.5 points lower after six weeks than at baseline. That was 12.7 points lower (and thus better) than the reduction recorded from the placebo group. In the 20-milligram cohort, PANNS scores fell 17.9 points, which was 11.1 points lower than patients given a placebo.

Now what

If CVL-231 makes it all the way over the finish line, Pfizer's in line to receive milestone payments and a tiered royalty percentage that could top out in the mid-teens. This is the first clinical trial with this drug candidate, so there's still a lot that could go wrong before Cerevel Therapeutics ever makes a sale.

While CVL-231 winds its way along the development pathway, Cerevel will get lots of chances to impress investors. The company is currently running clinical trials with five different new drug candidates.

With a helping hand from Pfizer to develop a pipeline dripping with potential new blockbuster drugs, this biotech stock has a good chance at delivering long-term gains for patient investors.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cerevel Therapeutics Holdings, Inc. Stock Quote
Cerevel Therapeutics Holdings, Inc.
CERE
$34.43 (-1.23%) $0.43
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.75 (-0.72%) $0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.